Allucent launches decentralized clinical trial platform at 2023 World Orphan Drug Congress
Allucent announced the launch of its decentralized clinical trial platform, aiming to transform the landscape of medical research, at 2023 World Orphan Drug Congress. The innovative platform integrates blockchain technology, artificial intelligence (AI), and telemedicine to streamline and enhance the efficiency of clinical trials while prioritizing patient-centricity.
Traditional clinical trials often face numerous challenges such as limited patient participation, lengthy timelines, and high costs. Allucent’s decentralized approach aims to address these issues by leveraging blockchain’s immutable and transparent nature, ensuring data integrity and security throughout the trial process.
The platform utilizes AI algorithms to match patients with appropriate clinical trials, increasing patient engagement and diversity. By removing geographical limitations, Allucent enables global participation, providing a more comprehensive and representative sample for study cohorts. Through telemedicine capabilities, patients can access virtual visits and consultations, eliminating the need for physical site visits and enhancing convenience and accessibility.
Allucent’s decentralized clinical trial platform also offers significant benefits to researchers and sponsors. By digitizing and automating trial processes, it reduces administrative burdens and enables real-time data collection and analysis. This accelerates the overall trial timeline, allowing for faster insights and decision-making. Additionally, the platform facilitates secure and transparent collaboration among stakeholders, including researchers, healthcare providers, and regulators.
Read the full press release here.
